A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms TOURMALINE-MM1
  • Sponsors Takeda Oncology

    • Most Recent Events

    • 20 Oct 2017 Results of a pre-planned analysis assessing the efficacy and safety of ixazomib-lenalidomide-dexamethasone (IRd) versus placebo-Rd according to cytogenetic risk, published in the Blood.
    • 12 Aug 2017 Data from this and other trials (NCT00932698, NCT00963820, NCT01217957 ) was used to quantitatively characterize the benefit-risk profile of ixazomib in relapsed/refractory MM, results published in the Targeted Oncology
    • 25 Jun 2017 Results of an exploratory endpoint (healthcare resource utilization) analysis presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top